At a glance
- Originator Kyowa Hakko
- Class Small molecules
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Diabetes mellitus
Most Recent Events
- 25 Oct 2006 Discontinued - Preclinical for Diabetes mellitus in Japan (unspecified route)
- 01 Dec 2004 Kyowa Hakko exclusively licensed to Sanwa Kagaku Kenkyusho rights to its research and know-how in the field of diabetes
- 01 Jul 2004 KF 72926 is available for licensing (http://www.kyowa.co.jp/eng/)